VELARU GALACTIC EXHIBIT PACK — PHARMA / CLINICAL TRIALS
Jurisdiction: Global / Multi-jurisdiction (global)
Modality: Text / Chat
Program: Velaru Mandate Registry — Pharma / Clinical Trials (galactic_pharma)
Product ID: pharma:global:bundle:text
Vertical: pharma
Generated: 2026-08-11T00:23:11.156865Z
Authority: Global External Validation — 21 CFR Part 11 Clinical AI Audit Pack
Deadline: EU AI Act Annex III — healthcare/life sciences
Velaru verify: https://velaru.onrender.com/verify

EXHIBIT A — AI INVENTORY
[]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 Pharma / Clinical Trials",
  "exhibit_authority": "Global External Validation \u2014 21 CFR Part 11 Clinical AI Audit Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "GCP ICH E6",
    "EU AI Act Annex III",
    "ISO 42001",
    "NIST AI RMF 1.0",
    "OECD AI Principles"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release clinical batch / report adverse event",
  "third_party_verification": "https://velaru.onrender.com/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "Sponsors using vendor AI for protocol deviation detection \u2014 sponsor owns FDA finding, vendor owns nothing. \u00b7 Multinationals built for one jurisdiction fail exams in another \u2014 one receipt architecture, many filing packs.",
  "chain_integrity": {
    "depth": 39,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "21 CFR Part 11 already requires what Velaru does \u2014 not AI safety, compliance",
  "global_leaders_addressed": [
    "FDA",
    "Pfizer",
    "IQVIA",
    "Veeva",
    "EMA",
    "ISO",
    "NIST",
    "OECD"
  ]
}

MIRROR TRAP (regulatory insight)
Sponsors using vendor AI for protocol deviation detection — sponsor owns FDA finding, vendor owns nothing. · Multinationals built for one jurisdiction fail exams in another — one receipt architecture, many filing packs.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "483 observations",
    "body": "FDA inspection: show audit trail for AI-flagged deviation \u2014 altered records = criminal referral pattern.",
    "source": "vertical"
  },
  {
    "title": "ICH E6 GCP",
    "body": "AI-assisted monitoring must be in validation documentation \u2014 post-hoc PowerPoint fails.",
    "source": "vertical"
  },
  {
    "title": "Trial insurance",
    "body": "Clinical trial insurers now ask AI governance questionnaire \u2014 receipts beat questionnaires.",
    "source": "vertical"
  },
  {
    "title": "[Global / Multi-jurisdiction] Jurisdiction shopping ends",
    "body": "Regulators share examination findings via IAIS, IOSCO, Basel \u2014 governance gap in one market triggers another.",
    "source": "jurisdiction"
  },
  {
    "title": "[Global / Multi-jurisdiction] Vendor contract forum",
    "body": "AI vendor chooses Delaware law \u2014 deployer owns EU, UK, and US state fines simultaneously.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 0,
  "compliant": 0,
  "grace_period": 0,
  "non_compliant": 0,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: $200B+ pharma R&D · AI in trial design exploding
INSURANCE LINES: Product liability, Clinical trial E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.